





Brief Report 529

Vascular Manifestations of Tuberculous Meningitis: MR Angiography and Venography Study

Suprava Naik¹ Sanjeev Kumar Bhoi² Nerbadyswari Deep (Baq)¹ Sudipta Mohakud¹ Baijayantimala Mishra³ Anupam Dey⁴ Rajesh Kumar⁴ Gautom Kumar Saharia⁵ Mukesh Kumar²

| Neurosci Rural Pract 2022;13:529-536.

Address for correspondence Suprava Naik, MD, Department of Radiodiagnosis, All India Institute of Medical Sciences, Bhubaneswar, Odisha 751019, India (e-mail: drsuprava.rd@gmail.com).

Abstract

Purpose The purpose of this study is to evaluate magnetic resonance (MR) angiography (MRA) and venography (MRV) findings in tuberculous meningitis (TBM).

Methods Thirty consecutive patients of clinically diagnosed TBM were enrolled. Apart from T2-weighted imaging, T1-weighted imaging (T1WI), diffusion-weighted imaging, susceptibility-weighted imaging, fluid-attenuated inversion recovery, and postcontrast T1WI, time-of-flight (TOF) MRA and postcontrast MRV were done in all the patients. MRV was done after intravenous administration of qadolinium-based contrast agent followed by postcontrast T1WI. MRA and MRV findings were analyzed.

Results Mean age of the patients was 33.13 ± 14.93 years. Duration of symptom was 34.90 ± 33.82 (range: 10–150) days. Out of 30 patients, 11 were categorized as definite TBM and 19 probable TBM. Eighteen (60%) were grade I, 7 (23%) grade II, and 5 (16%) grade III TBM based on severity. MR abnormalities were in varying combinations of leptomeningeal enhancement in 24 (80%), pachymeningeal in 2, both in 3, tuberculomas in 13 (43.3%), ventriculitis in 1, hydrocephalus in 16 (53.3%), and infarcts in 10 (33.3%) patients out of which the tubercular zone infarct in 9 patients. TOF MRA showed arterial abnormality in 13 patients. Anterior cerebral artery and middle cerebral artery have commonly involved vessels. Dural sinus thrombosis was noted in two patients. Both were female. One patient had subacute thrombus in the posterior part of superior sagittal sinus, left transverse sinus, and proximal right transverse sinus. The second patient had a filling defect in the transverse sinus.

Conclusion In TBM, there is predominant arterial involvement causing infarcts which are usually seen in the tubercular zone. However, occasionally, there may be venous involvement causing cerebral venous sinus thrombosis.

Keywords

- meningitis
- MRV
- cerebral venous sinus thrombosis
- TBM

published online June 8, 2022

DOI https://doi.org/ 10.1055/s-0042-1748175. ISSN 0976-3147.

© 2022. Association for Helping Neurosurgical Sick People. All rights reserved.

This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/ licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd., A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

¹Department of Radiodiagnosis, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

²Department of Neurology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

³Department of Microbiology, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

 $^{^{}m 4}$ Department of Medicine, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

⁵Department of Biochemistry, All India Institute of Medical Sciences, Bhubaneswar, Odisha, India

Introduction

Tuberculous meningitis (TBM) is the most severe form of tuberculosis (TB) and a major health problem in developing countries. Central nervous system (CNS) TB accounts for 1% of all cases of TB and is a major cause of morbidity and mortality. Clinical spectrum of intracranial TB includes basal meningitis, leptomeningitis, pachymeningitis, tuberculomas, tubercular abscess, ventriculitis, hydrocephalus, and infarcts.² Cerebral venous sinus thrombosis (CVST) has been reported in other CNS infections. The presence of sinus thrombosis in CNS infection also increases the risk of death and disability in these patients.³ Arterial narrowing and infarcts are already established in TBM. There is a paucity of studies about the occurrence of CVST in TBM patients. In this article, we have analyzed arterial and venous sinus abnormality on magnetic resonance imaging (MRI) in TBM patients.

Materials and Methods

This is a cross-sectional observational study conducted in a tertiary care teaching institute after approval from the institute's ethics committee. Patients were recruited between January 2018 and April 2020 after obtaining written informed consent from the patient or their relatives.

Thirty consecutive patients with clinically diagnosed TBM were enrolled in this study. Detailed clinical evaluation, duration of illness, presence of seizure, focal neurological deficit, or altered sensorium was noted. Consciousness was assessed by Glasgow coma scale (GCS). Routine hematology and cerebrospinal fluid (CSF) examination were done in all the patients. Evidence of infective focus elsewhere in the body was evaluated that also added to the final diagnosis.

Diagnosis of TBM was made according to the following criteria^{4,5}:

Definite TBM: Patients having clinical symptoms of meningitis for > 10 days and presence of acid-fast bacillus in CSF or culture or a positive cartridge-based nucleic acid amplification test or polymerase chain reaction in CSF.

Probable TBM: Patients having clinical symptoms of meningitis for > 10 days with at least two of the following supportive criteria:

- 1. More than 20 cells in CSF with lymphocytic predominance, raised protein
- MRI findings of TBM (basal exudates, meningeal enhancement, hydrocephalous, vasculitic infarcts, tuberculoma in various combinations)
- 3. Presence of TB elsewhere in the body.

Based on the severity of meningitis, TBM cases were categorized as stage I (meningitis only), stage II (meningitis with focal neurological deficit or GCS score of 11–14), and stage III (meningitis with GCS score < 11).⁶

Imaging: MRI of the brain was done in a 1.5-T MRI scanner (Siemens Magnetom Aera) using 20 channel head coil. Apart from routine T2-weighted imaging, T1-weighted imaging (T1WI), diffusion-weighted imaging, susceptibility-weight-

ed imaging, fluid-attenuated inversion recovery, and post-contrast T1WI, three-dimensional (3D) time-of-flight MR angiography (TOF MRA) and contrast-enhanced MR venography (MRV) was done in all the patients. 3D TOF MRA was done using repetition time (TR) 24, echo time (TE) 7, and flip angle of 25 degrees. Postcontrast MRV was done after intravenous administration of 0.1 mg/kg dose gadolinium-based contrast agent (Magnilek) by care bolus technique with TR 3.1, TE 1.1 milliseconds. Postcontrast T1WI was also acquired after MRV. Postprocessing was done on the multipurpose workstation of Siemens.

MRI findings were analyzed for the presence or absence of leptomeningeal enhancement, pachymeningeal enhancement, basal exudates, tuberculomas, abscess, ventriculitis, hydrocephalus, and vasculitic infarcts. The location of the cerebral infarcts was documented. The location and characteristics of tuberculoma were noted. MRA and MRV abnormalities were also analyzed by two radiologists with more than 11 years of experience. Area of irregularity, narrowing, and the arteries involved were documented for major intracranial arteries. Arterial narrowing of more than 50% compared with the proximal normal arterial segment was considered as significant narrowing. The presence and location of infarcts were noted. Infarcts were categorized in the tubercular zone (caudate, lentiform nuclei, anterior limb and genu of internal capsule, and anterior thalamus) and ischemic zone (putamen, posterior limb of internal capsule, and posterolateral thalamus). Opacification of major dural sinuses on postcontrast venography and the presence of flow void in conventional sequences were considered normal. Hypoplastic right or left transverse sinus was also considered as a normal variant. Filling defects in the dural sinuses or deep cerebral veins were considered abnormal. The focal filling defect could be due to arachnoid granulations within the dural sinuses which are commonly seen in superior sagittal sinus and transverse sinus. If the focal filling defect within the sinus was linear and irregular, it was considered abnormal. MRV findings were correlated with signal in T1WI and T2WI in the corresponding areas. Statistical analysis was performed using SPSS version 15 (Chicago, Illinois, United States).

Results

A total of 30 patients with clinical features and CSF findings of confirmed or probable TBM were included in the study. The mean age of the patients was 33.13 ± 14.93 (range: 18-65 years); 56.7% were female. Duration of symptom was 34.90 ± 33.82 (range: 10-150) days. Details of demographic, clinical, and radiological findings in 30 TBM patients are described in **Table 1**. Out of the 30 TBM patients, 11 (36.7%) were categorized as definite TBM and 19 (63.3%) probable TBM. According to grade of TBM, 18 (60%) were grade I, 7 (23%) grade II, and 5 (16%) grade III TBM.

Twenty-nine TBM (96.7%) patients have an abnormality on MRI. MR abnormalities were in varying combinations of leptomeningeal enhancement in 24 (80%), pachymeningeal enhancement in 2 (6.7%), both lepto- and pachymeningeal

Table 1 Demographic, clinical, and radiological findings in 30 TBM patients

Mean age (in years) 33.13 ± 14.93 (range: 18-65) Gender (female/male) 17 (56.7)/13 (43.3) Clinical symptoms 34.90 ± 33.82 (10-150) Ever 30 (100%) Headache 28 (93.3%) Vomiting 17(56.7%) Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 6 (16%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 (%) Meningeal enhancement 29 (%) Pach	Variables	N=30 (%)	
Gender (female/male) (range: 18-65) Gender (female/male) 17 (56.7)/13 (43.3) Clinical symptoms 34.90 ± 33.82 (10−150) Fever 30 (100%) Headache 28 (93.3%) Vomiting 17(56.7%) Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 48/30 (60%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 4 Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24			
Clinical symptoms		(range: 18-65)	
Duration of symptom (in days) 34.90 ± 33.82 (10−150) Fever 30 (100%) Headache 28 (93.3%) Vomiting 17(56.7%) Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 18/30 (60%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal	Gender (female/male)	17 (56.7)/13 (43.3)	
symptom (in days) (10-150) Fever 30 (100%) Headache 28 (93.3%) Vomiting 17(56.7%) Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 3 (60%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) <t< td=""><td colspan="3">Clinical symptoms</td></t<>	Clinical symptoms		
Headache 28 (93.3%) Vomiting 17(56.7%) Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs Neck stiffness 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)			
Vomiting 17(56.7%) Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs 29 (%) Neck stiffness 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM Total cell (70%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Fever	30 (100%)	
Seizure 6 (20%) Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs 29 (%) Neck stiffness 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 3.47 ± 2.22 Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 3 Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Headache	28 (93.3%)	
Altered sensorium 19 (63.3%) Weakness 13 (43.3%) Signs Neck stiffness 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 16 (53.3%)	Vomiting	17(56.7%)	
Weakness 13 (43.3%) Signs 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 4bnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Seizure	6 (20%)	
Signs Neck stiffness 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM Total cells (70%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Altered sensorium	19 (63.3%)	
Neck stiffness 29 (%) Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 18/30 (60%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 2 Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Weakness	13 (43.3%)	
Kernig sign 9 (30%) Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 18/30 (60%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 2 Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Signs	·	
Papilledema 8 (27%) GCS 13.47 ± 2.22 Grade of TBM 18/30 (60%) Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 2 Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Neck stiffness	29 (%)	
GCS 13.47 ± 2.22 Grade of TBM Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Kernig sign	9 (30%)	
Grade of TBM Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72±331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71±162.85 Sugar (mg/dL) 45.22±25.86 ADA (IU/L) 20.89±23.13 CBNAAT/PCR 9 AFB 2 MRI findings 2 Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Papilledema	8 (27%)	
Grade 1 18/30 (60%) Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	GCS	13.47 ± 2.22	
Grade 2 7 (23%) Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72±331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71±162.85 Sugar (mg/dL) 45.22±25.86 ADA (IU/L) 20.89±23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Grade of TBM		
Grade 3 5 (16%) CSF findings Total cells (/mm³) 249.72±331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71±162.85 Sugar (mg/dL) 45.22±25.86 ADA (IU/L) 20.89±23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Grade 1	18/30 (60%)	
CSF findings Total cells (/mm³) 249.72±331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71±162.85 Sugar (mg/dL) 45.22±25.86 ADA (IU/L) 20.89±23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Grade 2	7 (23%)	
Total cells (/mm³) 249.72 ± 331.59 Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Grade 3	5 (16%)	
Lymphocytic predominance 25/30 Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	CSF findings		
Protein (mg/dL) 241.71 ± 162.85 Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Total cells (/mm³)	249.72 ± 331.59	
Sugar (mg/dL) 45.22 ± 25.86 ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Lymphocytic predominance	25/30	
ADA (IU/L) 20.89 ± 23.13 CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Protein (mg/dL)	241.71 ± 162.85	
CBNAAT/PCR 9 AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Sugar (mg/dL)	45.22 ± 25.86	
AFB 2 MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	ADA (IU/L)	20.89 ± 23.13	
MRI findings Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	CBNAAT/PCR	9	
Abnormal 29 (%) Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	AFB	2	
Meningeal enhancement 29 Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	MRI findings		
Pachy 2 Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Abnormal	29 (%)	
Lepto 24 Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Meningeal enhancement	29	
Both 3 None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Pachy	2	
None 1 Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Lepto	24	
Basal exudates 21 (70%) Hydrocephalus 16 (53.3%)	Both	3	
Hydrocephalus 16 (53.3%)	None	1	
	Basal exudates	21 (70%)	
Ventriculitie 1 /2 2%	Hydrocephalus	16 (53.3%)	
ventricultus [1 (3.3%)	Ventriculitis	1 (3.3%)	
Tuberculoma 13 (43.3%)	Tuberculoma	13 (43.3%)	
Vasculitic infarcts 10 (33.3%)	Vasculitic infarcts	10 (33.3%)	
Tubercular zone infarcts 9 (30%)	Tubercular zone infarcts	9 (30%)	
Ischemic zone infarcts 1 (3.3%)	Ischemic zone infarcts	1 (3.3%)	

Variables	N = 30 (%)
MRA abnormalities	13 (43.3%)
MRV abnormalities	2 (6.7%)
Category TBM	
Confirmed TBM (CSF AFB/CBNAAT/PCR positive)	11 (36.7%)
Probable TBM	19 (63.3%)
Evidence of extra-CNS TB	6 (20%)
Clinical outcome at discharge	
Improved	23 (76.7%)
Death	2 (6.7%)
Bed bound	5 (16.7%)
Better outcome	23 (76.7%)
Poor outcome	7 (23.3%)

Abbreviations: ADA, adenosine deaminase; AFB, acid-fast bacillus; CBNAAT, cartridge-based nucleic acid amplification test; CNS, central nervous system; GCS, Glasgow coma scale; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; MRV, magnetic resonance venography; PCR, polymerase chain reaction; TB, tuberculosis; TBM, tuberculous meningitis.

enhancement in 3 (10%), tuberculomas in 13 (43.3%), ventriculitis in 1 (3.3%), hydrocephalus in 16 (53.3%), and infarcts in 10 (33.3%), details given in -Table 1. Cerebral infarcts were seen in 10 (33.3%) patients, out of which the tubercular zone is involved in 9 patients. The representative image is given in **Fig. 1**.

Arterial abnormality on TOF MRA was noted in 13 (43.3%) patients. The significant arterial narrowing was noted in four patients, whereas mild irregularity of vessels was noted in nine patients. Anterior cerebral artery (ACA) was involved in five patients (bilateral in three and unilateral in two), middle cerebral artery (MCA) in seven patients (bilateral in two and unilateral in five), both MCA and ACA in two patients (left side), PCA in two (unilateral, one on right and one left), and supraclinoid internal carotid artery in two patients (unilateral on the right side).

Comparison of clinical and MRI parameters between TBM patients having normal and abnormal MRA findings is given in **Table 2**. GCS at admission was significantly lower in patients having abnormality in MRA compared with those without abnormality in MRA (p = 0.05). This was attributed to the presence of vasculitic infarcts in patients with abnormal MRA findings. Basal exudates and hydrocephalous were also significantly greater in patients with abnormal MRA findings (p = 0.02 and p = 0.03, respectively). The outcome is better in patients with normal MRA findings.

Abnormal MRV was noted in two (6.7%) of patients. Both were female. One patient had subacute thrombus in the posterior part of the superior sagittal sinus, left transverse sinus, and proximal right transverse sinus (►Fig. 2). The second patient had a partial filling defect in the nondominant transverse sinus. Details of the patients are given in ►Table 3. Both of our TBM patients having sinus

(Continued)




Fig. 1 Axial T2-weighted imaging (**A**) shows hyperintensity in the left perisylvian region and prominent temporal horn. Axial diffusion-weighted imaging (**B**) and apparent diffusion coefficient (**C**) show acute infarcts in the head of the left caudate and globus pallidum (arrows). Axial T1-weighted imaging (T1WI) (**D**) and postcontrast T1WI (**E**) show enhancement in the basal cisterns and bilateral Sylvian cistern. Time-of-flight magnetic resonance angiography (**F**) shows focal significant narrowing of the proximal left middle cerebral artery (arrowhead).

Table 2 Comparison of clinical symptom and imaging finding in TBM patients having normal and abnormal MRAs

	Abnormal MRA (n = 13)	Normal MRA (n = 17)	<i>p</i> -Value
Age (years)	32.77 ± 12.84	33.41 ± 16.73	0.91
Gender	Male 5, female 8	Male 8, female 9	
Duration of illness (days)	29.77 ± 27.98	38.82 ± 38.05	0.46
Seizure	2	4	0.59
GCS at admission	12±2	13.44 ± 1.75	0.053
Weakness	9 (69.2%)	4 (23.5%)	0.01
Altered sensorium	8	11 (64.7%)	0.86
CSF			
Cells	127.89 ± 108.277	318.25 ± 394.661	0.051
Proteins (/mm³)	187.7 ± 89.10	280.286 ± 193.85	0.253
Definite TBM (mg/dL)	7 (53.8%)	4 (30.8%)	0.79
Meningeal enhancement	13 (100%)	16(94.1%)	0.382
Basal exudates	12 (92.3%)	9 (52.9%)	0.02
Hydrocephalus	10 (76.9%)	6 (35.3%)	0.03
Ventriculitis	0	1 (5.9%)	0.38

Table 2 (Continued)

	Abnormal MRA (n = 13)	Normal MRA (n = 17)	<i>p</i> -Value
Tuberculoma	6 (46.2%)	7 (41.2%)	0.79
Vasculitic infarct	7 (53.8%)	3 (17.6%)	0.07
Outcome at discharge	9 (69.2%)	15 (88.2%)	0.17
Meningitis grade			
Grade 1	5 (38.5%)	12 (70.6%)	0.16
Grade 2	5 (38.5%)	2(11.8%)	
Grade 3	3 (23.1%)	3 (17.6%)	

Abbreviations: CSF, cerebrospinal fluid; GCS, Glasgow coma scale; MRA, magnetic resonance angiography; TBM, tuberculous meningitis.




Fig. 2 Axial postcontrast three-dimensional T1-weighted imaging (T1WI) sequence (A-C) shows multiple nodular and ring-enhancing lesions in the right frontal lobe, head of right caudate, and right cerebellum. Diffuse pachymeningeal enhancement was also noted. Axial T2-weighted imaging (D) and T1WI (E) show hyperintense thrombus in the posterior and anterior parts of the superior sagittal sinus (SSS) (arrows). Postcontrast magnetic resonance venography (F) shows filling defects in the posterior and anterior parts of SSS, right transverse sinus, and proximal left transverse sinus (arrowheads).

thrombosis improved after treatment. Two patients had hypoplastic left transverse sinus.

Discussion

TBM is the most severe form of extrapulmonary TB. Cerebrovascular complications in TBM have been reported as a poor prognostic predictor. Vascular complications associated with TBM are usually secondary to arteritis causing arterial vasculitic infarcts. We found cerebral infarcts in 10 out of 30 (33.3%) cases. Arterial narrowing and abnormalities were found in 13 (43.3%) patients in our study. Infarcts were noted in 10 (33.3%) out of which 9 were in the tubercular zone. Cerebrovascular infarcts are complications of TBM which

Table 3 Details of two TBM patients having sinus thrombosis

Parameters	Patient 1	Patient 2
Age, y/sex	23 y/F	27 y/F
	Definite TBM	Definite TBM
Grade of TBM	Grade 1	Grade 1
Clinical presentation	Low-grade fever for 3 mo, holocranial head- ache for 3 mo, loss of vision in both eyes for 20 d Bilateral papilledema present, DTR normal, bilateral plantar flexor, neck stiffness and Kernig sign was positive Hb 10.2 g%, TLC 9,200/mm³, and ESR was 34 mm at the end of 1 h	Low-grade fever, severe headache, and intermittent vomiting for 4 mo; blurring of vision for 2 mo Papilledema on right side, left optic atrophy Neck stiffness and Kernig sign was positive Hb 12.2 g%, TLC 11,870/mm³, and ESR was 40 mm at the end of 1 h
CSF		
Protein	96	86
Sugar (mg/dL)	20	53
Cells/mm ³	36 (lymphocytic predominance)	94 (lymphocytic predominance)
CBNAAT/PCR	Positive	Positive
MRI findings		
Meningeal enhancement	Diffuse pachymeningeal enhancement (predominantly frontoparietal)	Present (leptomeningeal enhancement)
Basal exudate	Absent	Present (perimesencephalic, prepontine cistern, and prechiasmal region)
Tuberculoma	Present (right caudate, frontal lobe, and right cerebellum)	Absent
Hydrocephalous	Absent	Present
Infarcts	Absent	Absent
MRA abnormality	Absent	Mild irregularity and narrowing of right cavernous, supraclinoid, and prox MCA
MRV abnormality	Present (filling defect in posterior aspect of superior sagittal sinus, left transverse sinus, and small part of right transverse sinus. Corresponding region shows loss of flow void and appears hyperintense on both T1W and T2W s/o subacute thrombus (Fig. 2)	Partial linear filling defect in right transverse and sigmoid sinus suggestive of thrombosis
Treatment	Antituberculous treatment (ATT) 3 d pulse methylprednisolone IV followed by oral steroid LMWH for 10 d	ATT 3 d pulse methylprednisolone IV followed by oral steroid LMWH for 10 d
Outcome	Improved at discharge	Improved clinically at discharge. Vision improved on right, but did not improve on left

Abbreviations: ATT, antituberculous treatment; CBNAAT, cartridge-based nucleic acid amplification test; CSF, cerebrospinal fluid; DTR, deep tendon reflex; ESR, erythrocyte sedimentation rate; IV, intravenous; LMWH, low-molecular-weight heparin; MCA, middle cerebral artery; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; MRV, magnetic resonance venography; PCR, polymerase chain reaction; TBM, tuberculous meningitis; TLC, total leukocyte count.

occurs in 15 to 57% of patients.⁷ In a study by Kalita et al, they found cerebral infarct in 50% of cases of TBM.⁸ In another retrospective study by Soni et al, they found cerebral infarcts in 57.7% of TBM patients.⁹ Cerebral infarcts in TBM are common and predominantly involve the perforator and cortical territory. In our study, most of the infarcts were in the tubercular zone which is like various previous studies. Arterial stroke has been reported in 15 to 67% of TBM patients and is associated with poor outcomes.^{7–12}

Venous pathology following intracranial TB is very rare. We found CVST in 6.7% patients of with TBM. Infection accounts for less than 10% of all causes of CVST, although TBM is a rare cause. There are few case reports of CVST in TBM. ^{13–15} In a large study by Bansod et al, abnormal MRV finding was noted in 12 (11.2%) out of 107 TBM patients. ¹⁶ In another study by Kalita et al, there was no evidence of venous thrombosis, although many variations in sinuses such as hypoplastic transverse sinus were seen. ⁸ Guenifi et al found 3 patients of CVST out of 61 patients of TBM. ¹⁷

Infectious causes of CVST are usually secondary to pyogenic meningitis, most common being sigmoid sinus and cavernous sinus thrombosis secondary to mastoiditis and sinusitis, respectively.³ Its occurrence in TBM is rare. There is also overlap in the clinical picture of TBM and CVST. So, the clinical presentation of CVST can be confused and falsely attributed to TBM. Contrast-enhanced MRI and MRV are the diagnostic modality of choice for TBM and CVST. Postcontrast T1WI shows meningeal enhancement, basal exudates which are features of tubercular meningitis. MRI can also show complications such as hydrocephalus and the mass effect of tuberculoma or tubercular abscess over the adjacent brain parenchyma. In CVST, there is loss of flow void in the dural sinuses in T1WI and T2WI and filling defects are seen in MRV.¹⁸

The pathophysiologic mechanism of CVST in the case of TBM may be due to endothelial injury, alteration in normal blood flow, and in blood coagulability. The hypercoagulable state occurs in patients with TB because they show increased platelet aggregability. Patients with underlying hypercoagulable states precipitate the occurrence of a thrombotic event. 14,19 TBM or tubercular exudate may cause endothelial injury by inflammatory infiltrates in their wall as it affects arteries. Alteration in prothrombotic status (protein C, protein S, antiphospholipid antibody syndrome) and increase in proinflammatory cytokines such as tumor necrosis factor-αand interleukin-6-secreting cells in peripheral blood mononuclear cells has been reported in patients infected with Mycobacterium tuberculosis.²⁰ In a histopathological study by Chatterjee et al, in 9 out of 51 cases of TBM, there was thrombophlebitis affecting medium-sized meningeal cortical veins.²¹

Venous abnormality in TBM is rare, although many cases and series have been reported. Timely management of TBM associated with CVST is important for a better prognosis. It is not always associated with poor outcomes if early treatment is provided. Antitubercular drugs are the mainstay of treatment in TBM with associated CVST. The role of anticoagulation in infective CVST is less defined. All the patients were treated with a standard antitubercular regimen and corticosteroid. Both the patients with CVST in our study were managed with an injection of low-molecular-weight heparin followed by oral anticoagulation tapered over 3 months. Both the patients were stable at the time of discharge and improved at 6 months follow-up.

The strength of our study is that it is a prospective study. We have done postcontrast MRV in all cases. However, this study has a few limitations. The sample size is small. Only adult patients were included. The number of confirmed TBM was comparatively less. Predisposing factors for CVST were not done in all patients. A larger study is required to know any association of tubercular meningitis with CVST.

Conclusion

CVST in tubercular meningitis is rare and the clinical pictures may be overlapping. Early diagnosis and management are required for better outcome of the patient. Contrast-enhanced MRV with postcontrast T1WI is required for diagnosis of sinus thrombosis and meningitis. In TBM, there is predominant arterial involvement causing infarcts. However, occasionally, there may be venous involvement causing CVST

Ethical Approval

Ethical approval obtained from Institutional Ethics Committee, AIIMS, Bhubaneswar.

Authors' Contributions

S.N. contributed to conceptualization, design, data analysis, literature search, manuscript editing, and manuscript review. S.K.B. helped in data analysis, literature search, manuscript editing, and manuscript review. N.D.(B.), S.M., B.M., A.D., R.K., G.K.S., and M.K. helped in manuscript editing and manuscript review.

Funding

Institutional intramural grant was received.

Conflict of Interest None declared.

References

- 1 Phypers M, Harris T, Power C. CNS tuberculosis: a longitudinal analysis of epidemiological and clinical features. Int J Tuberc Lung Dis 2006;10(01):99–103
- 2 Changal KH, Raina AH. Central nervous system manifestations of tuberculosis: a review article. J Mycobac Dis 2014;4:146
- 3 Ferro JM, Canhão P, Stam J, Bousser MG, Barinagarrementeria FISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35(03):664–670
- 4 Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351(17):1741–1751
- 5 Misra UK, Kalita J, Sagar B, Bhoi SK. Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis? Neurol India 2018;66(06):1672–1677
- 6 Kalita J, Misra UK, Nair PP. Predictors of stroke and its significance in the outcome of tuberculous meningitis. J Stroke Cerebrovasc Dis 2009;18(04):251–258
- 7 Misra UK, Kalita J, Maurya PK. Stroke in tuberculous meningitis. J Neurol Sci 2011;303(1-2):22–30
- 8 Kalita J, Singh RK, Misra UK, Kumar S. Evaluation of cerebral arterial and venous system in tuberculous meningitis. J Neuroradiol 2018;45(02):130–135
- 9 Soni N, Kumar S, Shimle A, Ora M, Bathla G, Mishra P. Cerebrovascular complications in tuberculous meningitis-a magnetic resonance imaging study in 90 patients from a tertiary care hospital. Neuroradiol J 2020;33(01):3–16
- 10 Lu TT, Lin XQ, Zhang L, et al. Magnetic resonance angiography manifestations and prognostic significance in HIV-negative tuberculosis meningitis. Int J Tuberc Lung Dis 2015;19(12):1448–1454
- 11 Wasay M, Khan M, Farooq S, et al. Frequency and impact of cerebral infarctions in patients with tuberculous meningitis. Stroke 2018;49(10):2288–2293
- 12 Tai MS, Viswanathan S, Rahmat K, et al. Cerebral infarction pattern in tuberculous meningitis. Sci Rep 2016;6:38802
- 13 Verma R, Lalla R, Patil TB, Tiwari N. A rare presentation of cerebral venous sinus thrombosis associated with tubercular meningitis. BMJ Case Rep 2013;2013:bcr2013009892

- 14 Fiorot Júnior JA, Felício AC, Fukujima MM, et al. Tuberculosis: an uncommon cause of cerebral venous thrombosis? Arq Neuropsiquiatr 2005;63(3B):852–854
- 15 Natarajan V, George S, Eapen G, Arulneyam J. An unusual association: tuberculous meningitis causing cerebral venous sinus thrombosis. J Case Report 2015;20;5(02):343–346
- 16 Bansod A, Garg RK, Rizvi I, et al. Magnetic resonance venographic findings in patients with tuberculous meningitis: predictors and outcome. Magn Reson Imaging 2018;54:8–14
- 17 Guenifi W, Boukhrissa H, Gasmi A, et al. Cerebral venous thrombosis during tuberculous meningoencephalitis [in French]. J Mal Vasc 2016;41(03):210–214
- 18 Masuhr F, Mehraein S, Einhäupl K. Cerebral venous and sinus thrombosis. J Neurol 2004;251(01):11–23
- 19 Robson SC, White NW, Aronson I, Woollgar R, Goodman H, Jacobs P. Acute-phase response and the hypercoagulable state in pulmonary tuberculosis. Br J Haematol 1996;93(04):943–949
- 20 Ogawa T, Uchida H, Kusumoto Y, Mori Y, Yamamura Y, Hamada S. Increase in tumor necrosis factor alpha- and interleukin-6-secreting cells in peripheral blood mononuclear cells from subjects infected with Mycobacterium tuberculosis. Infect Immun 1991;59(09):3021–3025
- 21 Chatterjee D, Radotra BD, Vasishta RK, Sharma K. Vascular complications of tuberculous meningitis: An autopsy study. Neurol India 2015;63(06):926–932